We showed that CRISPR/Cas9 system delivered by hydrodynamic tail vein injection can be used to somatically induce p53 and Pten mutation in the liver of HBV-transgenic mice, leading to the induction of HCC as early as 4 months’ post injection. Here, TP53 is linked to hepatocellular carcinoma.